Pharmabiz9h
Leucine Rich Bio unveils #HappyGutMission campaign, survey indicates 29.7% individuals report frequent antibiotic use
Leucine Rich Bio, now unveils its #HappyGutMission campaign an initiative designed to educate people on the critical role of gut health. This campaign has brought gut health to the forefront, offering ...
Pharmabiz6h
Paratek Pharma announces positive top-line data from phase 2b study of oral omadacycline in NTM abscessus pulmonary disease
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for serious diseases, announced top-line ...
Pharmabiz21h
Ayush and herbal products exports grow over 10 per cent in H1 FY25
Exports of Ayush and herbal products for the first six months of the current fiscal has reported a 10.34 per cent growth, as ...
Pharmabiz12h
Harbour BioMed submits IND application for HBM9378/SKB378 to China NMPA to treat chronic obstructive pulmonary disease
Harbour BioMed submits IND application for HBM9378/SKB378 to China NMPA to treat chronic obstructive pulmonary disease: Suzhou, China Monday, November 11, 2024, 17:00 Hrs [IST] Ha ...
Pharmabiz13h
Dr Jayachandra Babu Ramapuram receives 2024 AAPS Fellow Award
Dr Jayachandra Babu Ramapuram has been honoured with the prestigious AAPS Fellow Award at the American Association of Pharmaceutical Scientists (AAPS) annual meeting held in Salt Lake City, Utah. This ...
Pharmabiz13h
Robles BioCeutics collaborates with BioCentrium to explore the molecular mechanisms behind Glowselle stem cell activator
Robles BioCeutics collaborates with BioCentrium to explore the molecular mechanisms behind Glowselle stem cell activator: San Diego Monday, November 11, 2024, 16:00 Hrs [IST] Robl ...
Pharmabiz12h
UDF to organize experts meeting towards creation of Indian Pharmaceutical Regulatory Service cadre
UDF to organize experts meeting towards creation of Indian Pharmaceutical Regulatory Service cadre: Shardul Nautiyal, Mumbai Monday, November 11, 2024, 16:45 Hrs [IST] New Delhi b ...
Pharmabiz14h
US FDA advisory panel votes in favour of IceCure's ProSense cryoablation benefit-risk profile in early-stage low risk breast cancer
IceCure Medical Ltd., a developer of minimally-invasive cryoablation technology that destroys tumours by freezing as an alternative to surgical tumour removal, announced the US Food and Drug ...
Pharmabiz13h
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Johnson & Johnson announced the submission of regulatory applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for Darzalex ...
Pharmabiz14h
EMA’s veterinary committee issues first certificate for vaccine platform technology master file
EMA's Committee for Veterinary Medicinal Products (CVMP) has issued the first certificate for a vaccine platform technology master file (vPTMF) which will support and accelerate the development and ...
Pharmabiz15h
US FDA clears SystImmune’s IND application for BL-M17D1 in advanced solid tumours
US FDA clears SystImmune’s IND application for BL-M17D1 in advanced solid tumours: Redmond, Washington Monday, November 11, 2024, 14:00 Hrs [IST] SystImmune, Inc (SystImmune), a ...
Pharmabiz11h
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...